Meyka Pro banner
Pembina Pipeline Corporation

Stay Updated with the Latest Pembina Pipeline Corporation PBA News in Real Time

Find PBA news now at Meyka AI. Stay informed with the latest Pembina Pipeline Corporation stocks updates, including price news, market analysis, and expert insights.

PBANYSE
EnergyOil & Gas Midstream
$48.59
$0.44(0.90%)
U.S. Market opens in 6h 2m
Partners Group Stock Drops 9.7% as H1 Profit Falls 13%, CEO to Step Down
📅 1 day ago

Partners Group Stock Drops 9.7% as H1 Profit Falls 13%, CEO to Step Down

Partners Group stock plunges 9.7% after H1 profit fell 13% to CHF 502 million. CEO David Layton to return to investment role; co-CEO structure returns January 2027.

Read more 12
HDFC Bank Shares Hit 52-Week Low as Jagdishan Steps Down in October
📅 1 day ago

HDFC Bank Shares Hit 52-Week Low as Jagdishan Steps Down in October

HDFC Bank CEO Sashidhar Jagdishan steps down in October 2026. Shares hit 52-week low of ₹704.15. Deputy MD Kaizad Bharucha leads internal succession race. Meyka rates stock B+.

Read more 12
Grand Canyon Flash Flood Kills 1, Leaves 15 Missing as Park Closes August 31
📅 2 days ago

Grand Canyon Flash Flood Kills 1, Leaves 15 Missing as Park Closes August 31

One dead, 15 missing after flash flood destroys Grand Canyon’s Phantom Ranch and infrastructure. Park closes all lodges; water pipeline damaged; more storms possible.

Read more 12
Grand Canyon Flash Flood Closes Phantom Ranch; 15 Unaccounted For on August 30
📅 3 days ago

Grand Canyon Flash Flood Closes Phantom Ranch; 15 Unaccounted For on August 30

Flash flooding at Grand Canyon National Park on August 29 evacuated 62 people from Phantom Ranch and closed trails indefinitely. About 15 remain unaccounted for as search efforts continue.

Read more 12
Itochu to Invest ¥250B in Dentsu Soken, Taking 38.2% Stake
📅 5 days ago

Itochu to Invest ¥250B in Dentsu Soken, Taking 38.2% Stake

Itochu to invest ¥250 billion for 38.2% stake in Dentsu Soken via tender offer. Move aims to resolve parent-subsidiary dual listing structure and expand Itochu’s IT segment.

Read more 12
MV Electrosystems Shares Jump 19% to Record High of ₹768 After Q1 Earnings Call
📅 6 days ago

MV Electrosystems Shares Jump 19% to Record High of ₹768 After Q1 Earnings Call

MV Electrosystems shares surged 18.7% to a record intraday high of ₹768 on August 28, 2026, after the company’s Q1 FY27 earnings call. The rally came despite weak quarterly profitability, with investors instead focusing on its nearly ₹1,000 crore order book and plans to improve margins. The stock has gained strong momentum since its recent…

Read more 12
Hindustan Copper in Focus: AGM to Consider QIP of Up to 9.7 Crore Shares, ₹500 Crore NCD
📅 6 days ago

Hindustan Copper in Focus: AGM to Consider QIP of Up to 9.7 Crore Shares, ₹500 Crore NCD

Hindustan Copper shares stayed in focus as shareholders prepare to vote on a major fundraising plan at the company’s 59th AGM. The board seeks approval for a Qualified Institutional Placement of up to 9,69,76,680 equity shares, each carrying a ₹5 face value. A separate resolution proposes issuing NCDs or bonds worth up to ₹500 crore…

Read more 12
Indian Stock Market Today: SENSEX Jumps 350 Points, NIFTY50 Above 24,150 as IT Stocks Rally
📅 6 days ago

Indian Stock Market Today: SENSEX Jumps 350 Points, NIFTY50 Above 24,150 as IT Stocks Rally

Indian stock market indices extended gains through Friday morning, August 28, 2026, led by a sharp IT sector rally. The Sensex climbed roughly 366 points, or 0.47%, to near 77,295. The Nifty50 pushed past 24,168, building on its early gains. Nifty IT rose over 1% as traders awaited Fed Chair Kevin Warsh’s Jackson Hole remarks….

Read more 12
AstraZeneca (AZN) and Amgen’s Tezspire Succeeds in Late-Stage Oesophagus Disease Trial
📅 7 days ago

AstraZeneca (AZN) and Amgen’s Tezspire Succeeds in Late-Stage Oesophagus Disease Trial

AstraZeneca said Thursday its drug Tezspire met all primary and secondary goals in a late-stage trial. The Phase III CROSSING trial tested Tezspire against placebo in eosinophilic oesophagitis (EoE). AstraZeneca developed the drug jointly with Amgen for this chronic inflammatory oesophagus condition. What the CROSSING Trial Showed The Phase III CROSSING trial evaluated two once-every-four-week…

Read more 12

PBA News FAQ